Lisa Kurtz

Lisa Kurtz

Auto-generated profile, based on publicly available information

Lisa Kurtz

Department of Genetics, University of North Carolina, Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Open access
PDF file
CJCynthia A. James
Cynthia A. James
JJJan D.H. Jongbloed
Jan D.H. Jongbloed
RHRay E. Hershberger
Ray E. Hershberger
AMAna Morales
Ana Morales
DJDaniel Judge
Daniel Judge
JTJ.Peter van Tintelen
J.Peter van Tintelen
Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disease characterized by ventricular arrhythmias and progressive ventricular dysfunction. Genetic testing is recommended, and a pathogenic variant in an ARVC-associated gene is a major criterion for diagnosis according to the 2010 Task Force Criteria. As incorrect attribution of a gene to ARVC can contribute to misdiagnosis, we assembled an international multidisciplinary ARVC Clinical Genome Resource Gene Curation Expert Panel to reappraise all reported ARVC genes. Methods: Following a comprehensive literature search, six 2-member teams conducted blinded independent curation of reported ARVC genes using the semiquantitative Clinical Genome Resource framework. Results: Of 26 reported ARVC genes, only 6 ( PKP2 , DSP , DSG2 , DSC2 , JUP , and TMEM43 ) had strong evidence and were classified as definitive for ARVC causation. There was moderate evidence for 2 genes, DES and PLN . The remaining 18 genes had limited or no evidence. RYR2 was refuted as an ARVC gene since clinical data and model systems exhibited a catecholaminergic polymorphic ventricular tachycardia phenotype. In ClinVar, only 5 pathogenic/likely pathogenic variants (1.1%) in limited evidence genes had been reported in ARVC cases in contrast to 450 desmosome gene variants (97.4%). Conclusions: Using the Clinical Genome Resource approach to gene-disease curation, only 8 genes ( PKP2 , DSP , DSG2 , DSC2 , JUP , TMEM43 , PLN , and DES ) had definitive or moderate evidence for ARVC, and these genes accounted for nearly all pathogenic/likely pathogenic ARVC variants in ClinVar. Therefore, only pathogenic/likely pathogenic variants in these 8 genes should yield a major criterion for ARVC diagnosis. Pathogenic/likely pathogenic variants identified in other genes in a patient should prompt further phenotyping as variants in many of these genes are associated with other cardiovascular conditions.

11 October 2018 in Human Mutation
Verified
Journal Article
Closed access
PDF file
EREdgar A. Rivera‐Muñoz
Edgar A. Rivera‐Muñoz
LMLaura Vogel Milko
Laura Vogel Milko
SHSteven Harrison
Steven Harrison
DADanielle R. Azzariti
Danielle R. Azzariti
CKC. Lisa Kurtz
C. Lisa Kurtz
JBJonathan S. Berg
Jonathan S. Berg

27 June 2012 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
AHA H Harrill
A H Harrill
JRJ Roach
J Roach
IFI Fier
I Fier
JEJ S Eaddy
J S Eaddy
CKC L Kurtz
C L Kurtz
PWP B Watkins
P B Watkins
Heparins have been reported to cause elevations in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) but have not been associated with clinically significant liver injury. The mechanisms underlying these benign laboratory abnormalities are unknown. Forty-eight healthy men were randomized to receive subcutaneous injections of unfractionated heparin (UFH; 150 U/kg), enoxaparin sodium (1 mg/kg), dalteparin sodium (120 IU/kg), or adomiparin sodium (125 IU/kg; a novel heparin) every 12 h for 4.5 days. Asymptomatic elevations in serum ALT or AST were observed in >90% of the subjects. Elevations were also observed in the levels of serum sorbitol dehydrogenase (SDH), glutamate dehydrogenase (GLDH), miR-122, high-mobility group box-1 protein (including the acetylated form), full-length keratin 18, and DNA. Keratin 18 fragments, which are apoptosis biomarkers, were not detected. Biomarker profiles did not differ significantly across heparin treatments. We conclude that heparins as a class cause self-limited and mild hepatocyte necrosis with secondary activation of an innate immune response.

22 December 2015 in Frontiers in Genetics
Verified
Journal Article
Open access
JBJeanette Baran-Gale
Jeanette Baran-Gale
CKC. Lisa Kurtz
C. Lisa Kurtz
MEMichael R. Erdos
Michael R. Erdos
CSChristina Sison
Christina Sison
AYAlice Young
Alice Young
PSPraveen Sethupathy
Praveen Sethupathy
Recent advances in sequencing technology have helped unveil the unexpected complexity and diversity of small RNAs. A critical step in small RNA library preparation for sequencing is the ligation of adapter sequences to both the 5’ and 3’ ends of small RNAs. Studies have shown that adapter ligation introduces a significant but widely unappreciated bias in the results of high-throughput small RNA sequencing. We show that due to this bias the two widely used Illumina library preparation protocols produce strikingly different microRNA (miRNA) expression profiles in the same batch of cells. There are 102 highly expressed miRNAs that are >5-fold differentially detected and some miRNAs, such as miR-24-3p, are over 30-fold differentially detected. While some level of bias in library preparation is not surprising, the apparent massive differential bias between these two widely used adapter sets is not well appreciated. In an attempt to mitigate this bias, the new Bioo Scientific NEXTflex V2 protocol utilizes a pool of adapters with random nucleotides at the ligation boundary. We show that this protocol is able to detect robustly several miRNAs that evade capture by the Illumina-based methods. While these analyses do not indicate a definitive gold standard for small RNA library preparation, the results of the NEXTflex protocol do correlate best with RT-qPCR. As increasingly more laboratories seek to study small RNAs, researchers should be aware of the extent to which the results may differ with different protocols, and should make an informed decision about the protocol that best fits their study.

16 August 2014 in Diabetes
Verified
Journal Article
Open access
PDF file
CKC. Lisa Kurtz
C. Lisa Kurtz
BPBailey C.E. Peck
Bailey C.E. Peck
EFEmily E. Fannin
Emily E. Fannin
CBCarine Beysen
Carine Beysen
JMJi Miao
Ji Miao
PSPraveen Sethupathy
Praveen Sethupathy
MicroRNAs (miRNAs) have emerged as biomarkers of metabolic status, etiological factors in complex disease, and promising drug targets. Recent reports suggest that miRNAs are critical regulators of pathways underlying the pathophysiology of type 2 diabetes. In this study, we demonstrate by deep sequencing and real-time quantitative PCR that hepatic levels of Foxa2 mRNA and miR-29 are elevated in a mouse model of diet-induced insulin resistance. We also show that Foxa2 and miR-29 are significantly upregulated in the livers of Zucker diabetic fatty (fa/fa) rats and that the levels of both returned to normal upon treatment with the insulin-sensitizing agent pioglitazone. We present evidence that miR-29 expression in human hepatoma cells is controlled in part by FOXA2, which is known to play a critical role in hepatic energy homeostasis. Moreover, we demonstrate that miR-29 fine-tunes FOXA2-mediated activation of key lipid metabolism genes, including PPARGC1A, HMGCS2, and ABHD5. These results suggest that miR-29 is an important regulatory factor in normal metabolism and may represent a novel therapeutic target in type 2 diabetes and related metabolic syndromes.

11 October 2018 in Human Mutation
Verified
Journal Article
Open access
PDF file
MIMichael A. Iacocca
Michael A. Iacocca
JCJoana Rita Chora
Joana Rita Chora
ACAlain Carrié
Alain Carrié
TFTomáš Freiberger
Tomáš Freiberger
SLSarah E. Leigh
Sarah E. Leigh
OPon behalf of the ClinGen FH Variant Curation Expert Panel
on behalf of the ClinGen FH Variant Curation Expert Panel
Accurate and consistent variant classification is imperative for incorporation of rapidly developing sequencing technologies into genomic medicine for improved patient care. An essential requirement for achieving standardized and reliable variant interpretation is data sharing, facilitated by a centralized open‐source database. Familial hypercholesterolemia (FH) is an exemplar of the utility of such a resource: it has a high incidence, a favorable prognosis with early intervention and treatment, and cascade screening can be offered to families if a causative variant is identified. ClinVar, an NCBI‐funded resource, has become the primary repository for clinically relevant variants in Mendelian disease, including FH. Here, we present the concerted efforts made by the Clinical Genome Resource, through the FH Variant Curation Expert Panel and global FH community, to increase submission of FH‐associated variants into ClinVar. Variant‐level data was categorized by submitter, variant characteristics, classification method, and available supporting data. To further reform interpretation of FH‐associated variants, areas for improvement in variant submissions were identified; these include a need for more detailed submissions and submission of supporting variant‐level data, both retrospectively and prospectively. Collaborating to provide thorough, reliable evidence‐based variant interpretation will ultimately improve the care of FH patients.